CompletedPhase 2/3

Fenofibrate in Ulcerative Colitis

Egypt60 participantsStarted 2023-02-28

Plain-language summary

Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Both males and females will be included * Negative pregnancy test and effective contraception. * Mild and moderate UC patients diagnosed and confirmed by an endoscope Exclusion Criteria: * Breastfeeding * Significant liver and kidney function abnormalities * Colorectal cancer patients * Other inflammatory bowel diseases (CD). * Patients with severe UC * Patients taking rectal or systemic steroids * Patients taking immunosuppressives or biological therapies * Addiction to alcohol and/or drugs * Known allergy to the Fenofibrate

What they're measuring

The primary endpoint is the change in disease activity index and the improvement in health-related quality of life (HRQL)

Timeframe: 6 months

Trial details

NCT IDNCT05753267

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-20

View on ClinicalTrials.gov More Inflammatory Bowel Diseases trials